[Dichloromethylenbiphosphonic acid in the therapy of myositis ossificans progressive (MOP)].
The authors report 3 cases of myositis ossificans progressiva (MOP) treated with i.v. dichloromethylenbiphosphonic acid. Two of these patients presented a severe development of the disease so that they could not walk anymore. After a few months of treatment with dichloromethylenbiphosphonic acid (300 mg/die for 10 continual days every month) sufficient recovery in motor capacity was achieved that walking was possible again. The favourable effect of therapy has been shown only by clinical features because there is no biological marker to monitor in the follow-up. During the treatment no side effect or modification of the markers of liver and kidney activity was observed.
Alpigiani
M G
MG
I Clinica Pediatrica, Istituto Giannina Gaslini, Università degli Studi, Genova.
Puleo
M G
MG
Callegarini
L
L
Di Bella
E
E
Debbia
C
C
Buzzanca
C
C
Iester
A
A
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004002:Clodronic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D009221:Myositis Ossificans / Q000188:drug therapy*; D011596:Psychomotor Disorders
D004002:Clodronic Acid
L'acido diclorometilenbifosfonico nella terapia della miosite ossificante progressiva.